- Home
- UCL vs XGN Comparison
UCL vs XGN Comparison
Compare UCL & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- XGN
- Stock Information
- Founded
- UCL 2014
- XGN 2002
- Country
- UCL Hong Kong
- XGN United States
- Employees
- UCL N/A
- XGN N/A
- Industry
- UCL Telecommunications Equipment
- XGN Medical Specialities
- Sector
- UCL Consumer Discretionary
- XGN Health Care
- Exchange
- UCL Nasdaq
- XGN Nasdaq
- Market Cap
- UCL 48.4M
- XGN 49.4M
- IPO Year
- UCL 2020
- XGN 2019
- Fundamental
- Price
- UCL $1.25
- XGN $2.94
- Analyst Decision
- UCL
- XGN Buy
- Analyst Count
- UCL 0
- XGN 1
- Target Price
- UCL N/A
- XGN $7.00
- AVG Volume (30 Days)
- UCL 21.4K
- XGN 28.8K
- Earning Date
- UCL 11-13-2024
- XGN 11-11-2024
- Dividend Yield
- UCL N/A
- XGN N/A
- EPS Growth
- UCL N/A
- XGN N/A
- EPS
- UCL 0.12
- XGN N/A
- Revenue
- UCL $86,076,000.00
- XGN $56,660,000.00
- Revenue This Year
- UCL $11.23
- XGN $9.98
- Revenue Next Year
- UCL $27.52
- XGN $13.63
- P/E Ratio
- UCL $10.82
- XGN N/A
- Revenue Growth
- UCL 10.63
- XGN 7.05
- 52 Week Low
- UCL $1.16
- XGN $1.30
- 52 Week High
- UCL $2.96
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- UCL 42.38
- XGN 49.62
- Support Level
- UCL $1.21
- XGN $2.90
- Resistance Level
- UCL $1.29
- XGN $3.03
- Average True Range (ATR)
- UCL 0.07
- XGN 0.17
- MACD
- UCL -0.00
- XGN -0.02
- Stochastic Oscillator
- UCL 33.33
- XGN 44.19
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.